{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:59:14Z","timestamp":1760237954330,"version":"build-2065373602"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ecl.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:57:04Z","timestamp":1670288224000},"page":"101-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetic Kidney Care Redefined with a New Way into Remission"],"prefix":"10.1016","volume":"52","author":[{"given":"Nour","family":"Hammad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ecl.2022.08.002_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"24","key":"10.1016\/j.ecl.2022.08.002_bib3","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1098-3597(03)90014-7","article-title":"Diabetic nephropathy","volume":"5","author":"Rabkin","year":"2003","journal-title":"Clin Cornerstone"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2022.08.002_bib5","first-page":"S79","article-title":"Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney Disease and Increased Mortality Risk in Type 2 Diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib7","first-page":"585","article-title":"Economic burden of comorbid chronic kidney disease and diabetes","volume":"20","author":"McQueen","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes","volume":"310","author":"Mogensen","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2022.08.002_bib9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1681\/ASN.2013091004","article-title":"Renal outcomes in patients with type 1 diabetes and macroalbuminuria","volume":"25","author":"de Boer","year":"2014","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.47102\/annals-acadmedsg.V34N1p24","article-title":"Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria","volume":"34","author":"Lee","year":"2005","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib12","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2016","journal-title":"J\u00a0Nephropharmacology"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"10.1016\/j.ecl.2022.08.002_bib14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"7258","key":"10.1016\/j.ecl.2022.08.002_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ecl.2022.08.002_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"issue":"8335","key":"10.1016\/j.ecl.2022.08.002_bib17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","article-title":"Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy","volume":"1","author":"Parving","year":"1983","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.ecl.2022.08.002_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2337\/diaspect.28.3.175","article-title":"Hypertension Management in Diabetic Kidney Disease","volume":"28","author":"Patney","year":"2015","journal-title":"Diabetes Spectr Publ Am Diabetes Assoc"},{"key":"10.1016\/j.ecl.2022.08.002_bib19","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2022.08.002_bib20","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.2337\/dc19-S011","article-title":"11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41100-016-0028-0","article-title":"Dyslipidemia in diabetic nephropathy","volume":"2","author":"Kawanami","year":"2016","journal-title":"Ren Replace Ther"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2008.528","article-title":"Regression of glomerular injury by losartan in experimental diabetic nephropathy","volume":"75","author":"Teles","year":"2009","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ecl.2022.08.002_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3949\/ccjm.86a.18024","article-title":"ACE inhibitors and ARBs: Managing potassium and renal function","volume":"86","author":"Momoniat","year":"2019","journal-title":"Cleve Clin J Med"},{"issue":"12","key":"10.1016\/j.ecl.2022.08.002_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.08.002_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"For the IRbesartan MicroAlbuminuria Type 2 Diabetes Mellitus in Hypertensive Patients (IRMA2) Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure\u2013independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ecl.2022.08.002_bib27","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-Receptor Blockade versus Converting\u2013Enzyme Inhibition in Type 2 Diabetes and Nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1016\/j.ecl.2022.08.002_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.ecl.2022.08.002_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Ontarget Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2022.08.002_bib30","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/FJC.0000000000001248","article-title":"Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome","volume":"79","author":"Clements","year":"2022","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3949\/ccjm.88a.20190","article-title":"SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now","volume":"88","author":"Taliercio","year":"2021","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"10.1016\/j.ecl.2022.08.002_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ecl.2022.08.002_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2022.08.002_bib36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2022.08.002_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/jom-2020-0153","article-title":"SGLT2 inhibitors: a narrative review of efficacy and safety","volume":"121","author":"Nelinson","year":"2021","journal-title":"J\u00a0Osteopath Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.08.002_bib40","doi-asserted-by":"crossref","first-page":"0106","DOI":"10.31083\/j.rcm2303106","article-title":"Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease","volume":"23","author":"Nevola","year":"2022","journal-title":"Rev Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.ecl.2022.08.002_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib42","doi-asserted-by":"crossref","first-page":"e08878","DOI":"10.1016\/j.heliyon.2022.e08878","article-title":"Mitochondria-targeted drugs for diabetic kidney disease","volume":"8","author":"Mima","year":"2022","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.ecl.2022.08.002_bib43","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","article-title":"Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int Reports"},{"issue":"3","key":"10.1016\/j.ecl.2022.08.002_bib44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2215\/CJN.10650620","article-title":"Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery","volume":"16","author":"Oluwo","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib45","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ecl.2022.08.002_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients","volume":"2","author":"Ray","year":"2020","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-022-02182-4","article-title":"The emerging role of magnesium in CKD","volume":"26","author":"Sakaguchi","year":"2022","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2021111515","article-title":"Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate","volume":"33","author":"Harmacek","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"S1","key":"10.1016\/j.ecl.2022.08.002_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets","volume":"22","author":"Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.ecl.2022.08.002_bib50","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s13300-021-01085-z","article-title":"The Role of Finerenone in the Management of Diabetic Nephropathy","volume":"12","author":"Veneti","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ecl.2022.08.002_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib52","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertens (Dallas, Tex 1979)"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib53","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ecl.2022.08.002_bib54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ecl.2022.08.002_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A\u00a0randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J\u00a0Diabetes Complications"},{"issue":"23","key":"10.1016\/j.ecl.2022.08.002_bib56","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2022.08.002_bib57","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.xkme.2021.07.007","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review","volume":"3","author":"Daza-Arnedo","year":"2021","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.ecl.2022.08.002_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int"},{"issue":"33","key":"10.1016\/j.ecl.2022.08.002_bib60","doi-asserted-by":"crossref","first-page":"54821","DOI":"10.18632\/oncotarget.18962","article-title":"DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2022.08.002_bib62","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ecl.2022.08.002_bib64","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.ecl.2022.08.002_bib65","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2022.08.002_bib66","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ecl.2022.08.002_bib67","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.08.002_bib68","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2022.08.002_bib69","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of Lesions of Diabetic Nephropathy after Pancreas Transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.08.002_bib71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fcell.2020.00123","article-title":"Diverse Role of TGF-\u03b2 in Kidney Disease","volume":"8","author":"Gu","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"10.1016\/j.ecl.2022.08.002_bib72","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2008090931","article-title":"Pirfenidone Is Renoprotective in Diabetic Kidney Disease","volume":"20","author":"RamachandraRao","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2022.08.002_bib73","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for Diabetic Nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib75","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.ecl.2022.08.002_bib76","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2215\/CJN.07340521","article-title":"The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial","volume":"16","author":"Waijer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ecl.2022.08.002_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2016.08.022","article-title":"Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update","volume":"791","author":"Bhattacharjee","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.ecl.2022.08.002_bib78","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes care"},{"issue":"10","key":"10.1016\/j.ecl.2022.08.002_bib79","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/toxins11100578","article-title":"Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease","volume":"11","author":"Dou","year":"2019","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ckj\/sfx074","article-title":"Sevelamer reduces endothelial inflammatory response to advanced glycation end products","volume":"11","author":"Greg\u00f3rio","year":"2018","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1016\/j.ecl.2022.08.002_bib81","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.ecl.2022.08.002_bib82","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transpl"},{"issue":"28","key":"10.1016\/j.ecl.2022.08.002_bib83","doi-asserted-by":"crossref","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ecl.2022.08.002_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006800.pub2","article-title":"Pentoxifylline for diabetic kidney disease. Cochrane Kidney and Transplant Group, editor","author":"Shan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ecl.2022.08.002_bib85","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients with Diabetic Kidney Disease: The PREDIAN Trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.ecl.2022.08.002_bib86","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1271\/bbb.90938","article-title":"Cilostazol Ameliorates Nephropathy in Type 1 Diabetic Rats Involving Improvement in Oxidative Stress and Regulation of TGF-\u03b2 and NF-\u03baB","volume":"74","author":"Lee","year":"2010","journal-title":"Biosci Biotechnol Biochem"},{"issue":"11","key":"10.1016\/j.ecl.2022.08.002_bib87","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tem.2016.07.002","article-title":"Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms","volume":"27","author":"Gnudi","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2022.08.002_bib88","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4196\/kjpp.2020.24.5.403","article-title":"Cilostazol ameliorates diabetic nephropathy by inhibiting high glucose- induced apoptosis","volume":"24","author":"Chian","year":"2020","journal-title":"Korean J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.ecl.2022.08.002_bib89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-0002-3","article-title":"Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"45","author":"Tang","year":"2014","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.ecl.2022.08.002_bib91","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/emboj\/17.9.2596","article-title":"Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1","volume":"17","author":"Saitoh","year":"1998","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.ecl.2022.08.002_bib92","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of Selonsertib in Patients with Diabetic Kidney Disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ecl.2022.08.002_bib93","doi-asserted-by":"crossref","first-page":"20282","DOI":"10.3390\/ijms141020282","article-title":"Targeting of Rho Kinase Ameliorates Impairment of Diabetic Endothelial Function in Intrarenal Artery","volume":"14","author":"Yin","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1\u20133","key":"10.1016\/j.ecl.2022.08.002_bib94","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejphar.2007.04.011","article-title":"The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats","volume":"568","author":"Gojo","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.ecl.2022.08.002_bib96","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.115.230706","article-title":"A\u00a0Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat","volume":"356","author":"Boustany-Kari","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:04Z","timestamp":1760176084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0889852922000809"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.08.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic Kidney Care Redefined with a New Way into Remission","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}